Republicans recently pounced on the fact that, yes, some Americans will lose their current crummy insurance plans that don't meet the new standards set by the Affordable Care Act.
These Republicans are accusing President Obama of having misled the American public -- or worse, having lied.
I think that's a ridiculous claim. If you like your crummy plan, you can't keep your crummy plan under Obamacare, but odds are you will find a better plan that is also more affordable, with subsidies available to more than half of Americans.
Aside from parsing this promise that you could keep your plan, it is wrong to say that this alone was how Obamacare was sold to the public.
Hot Asian Companies To Invest In 2015: Vimicro International Corporation(VIMC)
Vimicro International Corporation, through its subsidiaries, designs, develops, and markets mixed-signal semiconductor products and system-level solutions for the consumer electronics, communications, and surveillance markets in Mainland China, Taiwan, Japan, Korea, and Hong Kong. It provides mixed-signal multimedia processors for personal computer and embedded notebook cameras, as well as for mobile phones. The company also offers system-level solutions that include integrated semiconductors, customizable firmware and software, software development tools, reference designs, and applications support. In addition, it provides security and surveillance products comprising video capturing, compression, transmission, storage, processing, display, and video analysis products. Further, the company involves in packaging, testing, and reselling third party image sensors. It sells its multimedia processor products through direct sales force and distributors to original design manuf acturers, original equipment manufacturers, design houses, and module manufacturers, as well as its security and surveillance products to government entities, telecommunications operators, schools, banks, railway companies, supermarkets, and theaters. The company was founded in 1999 and is based in Beijing, the People?s Republic of China.
Advisors' Opinion:- [By John Udovich]
Small cap security and surveillance stocks like Vimicro International Corporation (NASDAQ: VIMC), TASER International, Inc (NASDAQ: TASR), Kratos Defense & Security Solutions, Inc (NASDAQ: KTOS)�and View Systems Inc (OTCBB: VSYM) have been producing a steady stream of news lately for investors and traders alike to digest. After all, the entire�security and surveillance industry is pretty vast as it would include everything from airport scanners to security cameras or monitoring equipment to actual weapons for domestic or national defense to software securing everyone�� personal or online data to the technology groups like the NSA and other "Big Brother" agencies use to spy on us. With that in mind, here is a look at the latest news from important small cap security and surveillance stocks:
- [By John Udovich]
Small cap security and surveillance stocks OSI Systems, Inc (NASDAQ: OSIS), Vimicro International Corporation (NASDAQ: VIMC), Analogic Corporation (NASDAQ: ALOG), Lifelock Inc (NYSE: LOCK) and View Systems Inc (OTCBB: VSYM) have been producing a steady flow of news lately that investors might want to take a closer look at. After all, the whole security and surveillance industry is pretty vast as it would include everything from airport scanners to security cameras to software securing everyone�� personal or online data. With that in mind, here is a look at the latest news from important small cap security and surveillance stocks:
Best Electric Utility Companies For 2014: BOK Financial Corporation(BOKF)
BOK Financial Corporation, a financial holding company, offers a range of financial products and services to commercial and industrial customers, and other financial institutions and consumers. It operates in three segments: Commercial Banking, Consumer Banking, and Wealth Management. The Commercial Banking segment offers lending, treasury, and cash management services; and customer risk management products to small businesses, middle market, and larger commercial customers. The Consumer Banking segment involves in retail lending and deposit services, and mortgage banking activities, as well as offers indirect automobile lending products. The Wealth Management segment provides fiduciary, brokerage and trading, private bank, and investment advisory services. As of December 31, 2010, the company operated 207 consumer banking locations, including branch banking locations and mortgage lending offices; and 1,943 ATM locations. BOK Financial Corporation operates in Oklahoma, Tex as, New Mexico, Northwest Arkansas, Colorado, Arizona, and Kansas/Missouri. The company was founded in 1910 and is headquartered in Tulsa, Oklahoma.
Advisors' Opinion:- [By John Maxfield]
Given that you clicked on this article, it seems safe to assume you either own stock in BOK Financial (NASDAQ: BOKF ) or are considering buying shares in the near future. If so, then you've come to the right place. The table below reveals the nine most critical numbers that investors need to know about BOK (which stands for "Bank of Oklahoma") before deciding whether to buy, sell, or hold its stock.
Best Electric Utility Companies For 2014: Research Frontiers Incorporated(REFR)
Research Frontiers Incorporated engages in the development, licensing, and marketing of technology and devices to control the flow of light. The company licenses its suspended particle device (SPD-Smart) light-control technology to companies that manufacture and market the SPD-smart chemical emulsion, light-control film made from chemical emulsion, lamination services, and electronics to power end-products incorporating the film; and end-products, such as windows, skylights, and sunroofs. The SPD-Smart light-control technology is used for various applications, such as windows, skylights, partitions, doors, and sunshades for the architectural, aircraft, marine, automotive, and appliance industries; variable light transmission sunglasses, goggles, visors, and other eyewear; variable light transmission automotive sunroofs, sunvisors, and rear-view mirrors; and flat panel information displays for use in billboards, scoreboards, point-of-purchase advertising displays, traffic s igns, computers, telephones, PDAs, and other electronic instruments. The company was founded in 1965 and is headquartered in Woodbury, New York.
Advisors' Opinion:- [By Garrett Cook]
In trading on Friday, cyclical consumer goods & services shares gained 0.61 percent. Top gainers in the sector included Nike (NYSE: NKE), up 10 percent, and Research Frontiers (NASDAQ: REFR), up 5.6 percent.
Best Electric Utility Companies For 2014: Coronado Biosciences Inc (CNDO)
Coronado Biosciences, Inc., incorporated on June 28, 2006, is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. The Company�� two principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201 (TSO) a biologic comprising of the microscopic eggs of the porcine whipworm, for the treatment of autoimmune diseases, such as Crohn�� disease (Crohn��), ulcerative colitis (UC) and multiple sclerosis (MS), and CNDO-109, a compound that activates natural killer (NK) cells of the immune system to seek and destroy cancer cells, for the treatment of acute myeloid leukemia (AML). In January 2011, the Company acquired the OvaMed GmbH License.
TSO
TSO is the microscopic eggs of a parasitic helminth, or worm, that is found in pigs. In September 2011, the Company filed an Investigational New Drug Application (IND) with the United States Food and Drug Administration (FDA) and it initiated a single dose, dose escalation study in patients with Crohn�� in February 2012. The Phase 1 clinical trial was a multi-center, sequential dose-escalation, double-blind, placebo-controlled study, the primary objective of which was to evaluate the safety and tolerability of TSO. The trial enrolled 36 patients with Crohn�� ranging in age from 20 to 54 with an equal distribution of male and female patients in three single dose cohorts of orally administered 500, 2500 and 7500 ova. Each cohort had 12 patients, with nine patients receiving TSO and three receiving placebo.
CNDO-109
CNDO-109 is a lysate (disrupted CTV-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor NK cells. CTV-1 is a leukemic cell line recently re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company has worldwide rights to develop and commercialize CNDO-109 activated NK cells for the treatment of cancer fro! m UCLB. In February 2012, the Company submitted an IND for the CNDO-109 activated NK cell product in the United States. The treatment of patients with CNDO-109 activated NK cells involves several steps. The activated NK cells are infused into the patient after resting NK cells are incubated with CNDO-109 for at least eight hours. Preparation of CNDO-109 activated NK cells takes about 24 hours from start to finish.
The Company competes with Centocor Ortho Biotech Inc.�� Remicade , UCB S.A.�� Cimzia, Abbott Laboratories��Humira, Biogen Idec�� Avonex, Bayer Healthcare Pharmaceuticals��Betaseron, Teva Pharmaceuticals Industries, Ltd.�� Copaxone and Novartis AG�� Gilenya.
Advisors' Opinion:- [By Roberto Pedone]
Coronado Biosciences (CNDO), a clinical stage biopharmaceutical company, focuses on the development of immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. This stock closed up 2.7% to $9.13 in Tuesday's trading session.
Tuesday's Range: $8.85-$9.58
52-Week Range: $4.00-$12.70
Tuesday's Volume: 1.31 million
Three-Month Average Volume: 419,038From a technical perspective, CNDO trended up here right above some near-term support at $8.79 with heavy upside volume. This move is starting to push shares of CNDO within range of triggering a near-term breakout trade. That trade will hit if CNDO manages to take out some near-term overhead resistance levels at $9.60 to $10.20 and then once it takes out more resistance at $10.35 with high volume.
Traders should now look for long-biased trades in CNDO as long as it's trending above its 50-day at $8.52 and then once it sustains a move or close above those breakout levels with volume that hits near or above 419,038 shares. If that breakout hits soon, then CNDO will set up to re-test or possibly take out its next major overhead resistance levels at $11 to $11.81. Any high-volume move above those levels will then put its all-time high at $12.70 into range for shares of CNDO.
- [By Roberto Pedone]
One under-$10 biopharmaceutical player that's quickly moving within range of triggering a major breakout trade is Coronado Biosciences (CNDO), which is focused on novel immunotherapy biologic agents for autoimmune diseases and cancer. This stock has been hit hard by the bears in 2013, with shares off by 43%.
If you take a look at the chart for Coronado Biosciences, you'll notice that this stock has been uptrending strong since it double bottomed in November, with shares moving higher from its low of $1.25 to its intraday high of $2.58 a share. During that uptrend, shares of CNDO have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of CNDO within range of triggering a major breakout trade.
Traders should now look for long-biased trades in CNDO if it manages to break out above some key overhead resistance at $2.70 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.97 million shares. If that breakout hits soon, then CNDO will set up to re-fill some of its previous gap down zone from October that started near $7 a share. Some possible upside targets if CNDO gets into that gap with volume are $4 to $5 a share.
Traders can look to buy CNDO off any weakness to anticipate that breakout and simply use a stop that sits right around some key near-term support at $2 a share. One can also buy CNDO off strength once it takes out $2.70 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Best Electric Utility Companies For 2014: 3D Systems Corp. (DDD)
3D Systems Corporation, through its subsidiaries, engages in the design, development, manufacture, marketing, and servicing of 3D printers and related products, print materials, and services. The company�s principle print engines comprise stereolithography, selective laser sintering, multi-jet modeling, film transfer imaging, selective laser melting, and plastic jet printers. Its 3D printers convert data input from computer-aided design software or 3D scanning and sculpting devices to produce physical objects from engineered plastic, metal, and composite print materials. The company also blends, markets, sells, and distributes various consumables, engineered plastics, metal materials, and composites; and offers various software tools, as well as pre-sale and post-sale services, including applications development, installation, warranty, and maintenance. In addition, it provides custom parts services, such as precision plastic and metal parts service and assembly capabilit ies. The company markets its stereolithography materials under the Accura and RenShape; laser sintering materials under the DuraForm, CastForm, and LaserForm; and materials for professional printers under the VisiJet brands. It primarily serves manufacturers of automotive, aerospace, computer, electronic, defense, education, consumer, energy and healthcare products, as well as original equipment manufacturers, government agencies, universities, and independent service bureaus. The company sells its products and services through its direct sales organization, sales agents, resellers, and distributors primarily in the United States, Europe, and the Asia-Pacific region. 3D Systems Corporation was founded in 1986 and is headquartered in Rock Hill, South Carolina.
Advisors' Opinion:- [By Vinay Singh]
Though the technology of 3D printing (additive manufacturing) is still in its early stages of development, many analysts are estimating that it will grow at a CAGR of 20%-30% for the next seven years and will nearly quadruple its value by 2020. It was widely assumed that the pioneer of the 3D printing industry, 3D Systems (DDD), was well positioned to capitalize on this growth, but the impending arrival of another big-name player in the form of Hewlett-Packard (HPQ) may restrict 3D Systems from fulfilling its potential.
- [By Selena Maranjian]
Finally, Fred Alger Management's biggest closed positions included QLIK Technologies�and Triumph Group. Other closed positions of interest include 3D Systems (NYSE: DDD ) and American Capital Agency (NASDAQ: AGNC ) . Many have high hopes for 3D Systems, but it hasn't been growing organically as quickly as some might like. The company's last earnings report was a bit mixed, with revenue up 31%, and net income dropping. But 3-D printing is still in its infancy, with much promise. Some see the shares as a bit rich now, though, and there has been insider selling. Another concern is that fellow 3D specialist Stratasys�is buying MakerBot�-- though there's a case to be made that the real future of 3D printing is in the commercial arena, not retail. Meanwhile, 3D Systems has been making some acquisitions of its own.
- [By MONEYMORNING.COM]
3D Systems Corp. (NYSE: DDD) is shouldering a short float of 33.1%, and its stock has dropped 7.4% in the past month. DDD is considered the premier company for 3D printing solutions and additive manufacturing, but as in the case with IRBT, skeptics are wary that any hype in this new technology is only feeding a bubble. Activist short seller Andrew Left of Citron Research was one of the more vocal detractors of the 3D printing phenomenon, and released a report in February that accused DDD executives of exaggerating progress in the industry to artificially inflate shares, according to Reuters.
- [By Steven Russolillo]
Stock in 3D Systems(DDD) bounced back after a choppy week, gaining 7% on Thursday, following a 5.3% loss on Tuesday and a 5.2% gain on Monday. On Tuesday, Canaccord Genuity raised its price target on the stock ahead of the annual Consumer Electronics Show in Las Vegas.
Best Electric Utility Companies For 2014: Prana Biotechnology Ltd (PRAN)
Prana Biotechnology Limited engages in the research and development of therapeutic drugs for the treatment of neurological disorders in Australia. The company primarily focuses on the Alzheimer�s, Parkinson�s, and Huntington�s diseases, as well as various cancer, age-related macular degeneration and cataract, Motor Neuron, and Creutzfeldt-Jakob diseases. Its development stage product line comprises PBT2, a Phase IIb clinical trial product for the treatment of Alzheimer�s disease; and PBT2, a Phase IIa clinical trial product for the treatment of Huntington�s disease. The company was formerly known as Prana Corporation Ltd. and changed its name to Prana Biotechnology Limited in January 2000. Prana Biotechnology Limited was founded in 1997 and is based in Parkville, Australia.
Advisors' Opinion:- [By Bryan Murphy]
Considering Eli Lilly & Co. (NYSE:LLY) as well as a co-development project between Johnson & Johnson (NYSE:JNJ) and Pfizer Inc. (NYSE:PFE) both failed in semi-recent effort to develop a similar-functioning Alzheimer's drug, it would be easy to assume that particular route towards an Alzheimer's might be the wrong path to take. Sometimes though, a small tweak or a seemingly-minor nuance with the underlying problem can make all the difference. Enter Prana Biotechnology Limited (NASDAQ:PRAN). Though the company acknowledges its focal point on the development of an Alzheimer's therapy is the same broad premise that ultimately led LLY, PFE, and JNJ to failure, PRAN may have found the proverbial missing link.
- [By John Udovich]
The biotech sector has been pretty exciting this year�with small cap biotech stocks Prana Biotechnology Limited (NASDAQ: PRAN) and TNI BioTech (OTCMKTS: TNIB) having recently produced noteworthy news for investors�while Acceleron Pharma, Inc (NASDAQ: XLRN), Ophthotech (NASDAQ: OPHT) and BIND Therapeutics (NASDAQ: BIND) have just�set term sheets for their upcoming IPOs. Just consider all of the following recent news:
No comments:
Post a Comment